Takayuki Nakagawa Selected Research

Sensorineural Hearing Loss

10/2020	Insulin-like growth factor 1: role in the auditory system and therapeutic potential in otology.
1/2020	Initiation of Supporting Cell Activation for Hair Cell Regeneration in the Avian Auditory Epithelium: An Explant Culture Model.
10/2016	Prognostic impact of salvage treatment on hearing recovery in patients with sudden sensorineural hearing loss refractory to systemic corticosteroids: A retrospective observational study.
12/2015	Insulin-like growth factor 1: A novel treatment for the protection or regeneration of cochlear hair cells.
5/2014	Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss.
1/2014	Strategies for developing novel therapeutics for sensorineural hearing loss.
9/2013	Insulin-like growth factor 1 inhibits hair cell apoptosis and promotes the cell cycle of supporting cells by activating different downstream cascades after pharmacological hair cell injury in neonatal mice.
1/2013	Systemic steroid application caused sudden death of a patient with sudden deafness.
8/2012	Audiometric outcomes of topical IGF1 treatment for sudden deafness refractory to systemic steroids.
1/2012	Identification of tympanic border cells as slow-cycling cells in the cochlea.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takayuki Nakagawa Research Topics

Disease

87	Neoplasms (Cancer) 12/2022 - 10/2002
20	Pain (Aches) 01/2021 - 10/2002
16	Lung Neoplasms (Lung Cancer) 06/2020 - 03/2012
15	Carcinoma (Carcinomatosis) 03/2021 - 04/2013
15	Sensorineural Hearing Loss 10/2020 - 12/2006
13	Inflammation (Inflammations) 01/2021 - 05/2005
13	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 07/2012
12	Melanoma (Melanoma, Malignant) 09/2022 - 07/2013
11	Hearing Loss (Hearing Impairment) 10/2020 - 01/2004
10	Breast Neoplasms (Breast Cancer) 04/2022 - 04/2013
10	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2003
10	Hypersensitivity (Allergy) 01/2021 - 07/2012
10	Wounds and Injuries (Trauma) 01/2019 - 02/2005
10	Hyperalgesia 01/2017 - 10/2002
7	Infections 01/2022 - 07/2003
7	Neuralgia (Stump Neuralgia) 07/2018 - 10/2002
7	Noise-Induced Hearing Loss (Acoustic Trauma) 05/2014 - 02/2005
6	Ischemia 10/2021 - 10/2008
6	Cold Hypersensitivity 12/2019 - 07/2012
5	Adenocarcinoma 09/2020 - 02/2012
5	Cystitis 01/2020 - 01/2013
5	Carcinogenesis 12/2018 - 01/2012
5	Labyrinth Diseases 07/2015 - 03/2004
4	Drug-Related Side Effects and Adverse Reactions 07/2019 - 01/2019
4	Hemorrhage 04/2019 - 02/2007
4	Sudden Hearing Loss (Sudden Deafness) 10/2016 - 08/2012
3	Squamous Cell Carcinoma of Head and Neck 12/2022 - 10/2006
3	Hypoxia (Hypoxemia) 05/2021 - 03/2016
3	Respiratory Insufficiency (Respiratory Failure) 01/2021 - 01/2019
3	Neuroblastoma 11/2018 - 10/2008

Drug/Important Bio-Agent (IBA)

16	Pharmaceutical PreparationsIBA 12/2019 - 01/2009
14	Tyrosine Kinase InhibitorsIBA 01/2017 - 01/2010
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2006
12	ErbB Receptors (EGF Receptor)IBA 01/2017 - 03/2012
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2021 - 10/2009
9	HydrogelsIBA 11/2014 - 04/2006
9	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2014 - 04/2009
8	Biomarkers (Surrogate Marker)IBA 09/2022 - 01/2013
8	MicroRNAs (MicroRNA)IBA 09/2022 - 01/2012
8	Messenger RNA (mRNA)IBA 04/2022 - 07/2003
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2019 - 07/2012
8	CrizotinibIBA 01/2019 - 07/2012
8	LigandsIBA 01/2017 - 10/2003
8	Gefitinib (Iressa)FDA Link 01/2015 - 03/2012
7	Analgesics (Analgesic Drugs)IBA 01/2021 - 10/2002
7	Phosphotransferases (Kinase)IBA 01/2021 - 10/2009
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 07/2012
7	CytokinesIBA 09/2020 - 09/2004
7	Morphine (MS Contin)FDA LinkGeneric 01/2019 - 02/2004
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2015 - 07/2012
7	GelatinIBA 11/2014 - 10/2007
6	Opioid Analgesics (Opioids)IBA 01/2021 - 01/2008
6	PlatinumIBA 12/2019 - 07/2012
6	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 01/2004
6	AnkyrinsIBA 01/2018 - 01/2016
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2017
5	Formaldehyde (Formol)FDA Link 03/2021 - 01/2007
5	Taxoids (Taxanes)IBA 01/2021 - 01/2017
5	Insulin-Like Growth Factor I (IGF-1)IBA 10/2020 - 04/2006
5	Insulin-Like PeptidesIBA 01/2019 - 10/2007
5	Glutamic Acid (Glutamate)FDA Link 07/2013 - 01/2004
4	RNA (Ribonucleic Acid)IBA 09/2022 - 12/2018
4	EnzymesIBA 04/2022 - 02/2005
4	AntigensIBA 01/2021 - 10/2002
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 04/2008
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018 - 01/2013
4	Adenosine Triphosphate (ATP)IBA 07/2018 - 10/2002
4	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 02/2017 - 01/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2014 - 09/2008
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2014 - 10/2009
4	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2014 - 07/2008
4	SteroidsIBA 01/2013 - 11/2010
3	LipidsIBA 05/2022 - 05/2017
3	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2013
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 01/2020
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 10/2009
3	taxaneIBA 01/2021 - 01/2018
3	NucleotidesIBA 01/2021 - 10/2002
3	Therapeutic UsesIBA 01/2021 - 03/2010
3	Liposomes (Liposome)IBA 01/2021 - 01/2017
3	Neutralizing AntibodiesIBA 01/2021 - 09/2012
3	Fentanyl (Sublimaze)FDA LinkGeneric 01/2021 - 01/2019
3	Clodronic Acid (Clodronate)IBA 01/2021 - 01/2017
3	Dinoprostone (PGE2)FDA Link 01/2021 - 01/2020
3	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 05/2003
3	C-Reactive ProteinIBA 11/2020 - 05/2005
3	human ERBB2 proteinIBA 06/2020 - 07/2019
3	Biological ProductsIBA 01/2020 - 06/2013
3	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 10/2019 - 11/2015
3	ChemokinesIBA 01/2018 - 04/2004
3	CalciumIBA 05/2017 - 08/2010
3	CarrageenanIBA 03/2015 - 12/2008
3	Insulin (Novolin)FDA Link 11/2014 - 04/2008

Therapy/Procedure

38	Therapeutics 01/2022 - 03/2004
11	Drug Therapy (Chemotherapy) 01/2021 - 01/2009
7	Ligation 11/2018 - 04/2004
5	Immunotherapy 01/2022 - 01/2017
5	Transplantation 01/2015 - 03/2004
4	Intravesical Administration 02/2017 - 01/2013
3	Injections 12/2019 - 01/2007